- Everyday Alpha
- Posts
- Why Big Money Is Loading Up on This Healthcare Compounder
Why Big Money Is Loading Up on This Healthcare Compounder
Three signals just lined up on a beaten-down mid-cap. The big funds noticed first.
A depressed valuation, steady institutional buying, and unusual options flow all point to the same mid-cap healthcare name.
September Catalyst Approaches (Sponsored)
The last time this firm did this, it skyrocketed overnight.
Now – backed by a $51 billion backlog, a SpaceX partnership, and President Trump’s ringing endorsement – the gains could be even bigger.
Get its stock symbol free of charge.
*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
The Cooper Companies, Inc.
August 26 – Pre‑market
Ticker: COO | Sector: Healthcare (Medical Instruments) | Market Cap: $14.17B
30‑Second Take
Why now? Cooper is a healthcare compounder with two sticky businesses: contact lenses and fertility products. Not exciting, but that is the point.
COO has been under pressure most of the year, and a few things have lined up at once for you. GuruFocus's valuation model has it trading roughly 27% below fair value. Ten of the 16 tracked institutional holders added to positions last quarter.
Add unusual call flow on the options desks, and the question becomes whether that valuation gap is enough to pull you in.
This is a defensive medical name with steady cash flow going on sale at a discount that does not usually stick around once the setup gets spotted. Fiscal Q3 earnings are two weeks out.
Trade Setup
Time frame: Swing to medium-term (6-12 weeks)
Edge type: Valuation dislocation plus institutional accumulation
Policy Watch (Sponsored)
There is speculation that Trump could sign an order updating how America's gold reserves are valued, a figure that has not changed since 1973.
Past resets of this kind have historically led to strong moves in related assets.
See what the order could mean for your money.
Poll: You find a stock that's down 60% from its high. The business is still profitable. What's your first move? |
|
Snapshot Table
Metric | Value | Current Stance |
|---|---|---|
Price | $73 | Bottom third of the 52-week range |
52‑week range | $59 - $90 | Closer to the low than the high |
Market Cap | $14.17B | Mid-cap medical device |
P/E Ratio | 61.7 trailing, 15.4 forward | GAAP earnings are depressed by charges, so the forward multiple is the honest read |
Beta | 0.82 | Less volatile than the market |
Avg Daily Volume | 2.6M | Liquid enough for any retail size |
Next Catalyst | Fiscal Q3 earnings, Wednesday, September 9, 4:15 PM ET | Two weeks out |
Chart
1-Month Synopsis: COO has clawed back roughly 4% over the past month after a brutal stretch earlier in the year, but it still sits in the bottom third of its 52-week range.
The medical device sector took a beating on GLP-1 demand fears and general risk-off pressure in healthcare, and Cooper got dragged along with it.
The interesting part is what is happening beneath the surface. Buying volume picked up on down days, which is usually the fingerprint of institutions accumulating into weakness rather than getting out.
Bull Case
Core thesis: Cooper runs two businesses, both boring in the best way. CooperVision sells contact lenses to a global user base that renews on autopilot. CooperSurgical serves the fertility and women's health market, one of the few reliably growing corners of med-tech you will find.
Neither segment is going to blow up on you. Neither reprices violently on macro noise.
Catalysts: The valuation gap is what makes this interesting. GuruFocus's fair value model shows COO trading roughly 27% below intrinsic value.
You do not often see a healthcare compounder with a beta under 1 on sale like that. And the market's reason for the discount, mostly GLP-1 spillover fear and generic med-device weakness, does not really touch the actual demand picture for contact lenses or fertility products.
Institutional accumulation is the tell. Ten of the 16 major guru funds tracked by GuruFocus added to their COO positions in the most recent filing period. Only three trimmed. When you see that ratio alongside rising call volume in the options market, something is usually cooking.
Big holders do not add on the way down without a thesis.
The near-term catalyst is fiscal Q3 earnings on September 9. Cooper has a habit of guiding conservatively and then delivering. If the print confirms that contact lens demand held up and fertility kept growing, you get multiple expansion off a depressed base.
That is where your return comes from.
Longer term, the fertility market itself is a structural tailwind. Delayed parenthood, IVF adoption, and better insurance coverage all point in one direction. Cooper's positioning there is underappreciated on the sell side.
Bear Case
The GLP-1 overhang is real, even if it is overstated for Cooper specifically. If the market decides weight-loss drugs are reshaping every corner of healthcare demand, defensive med-device names can stay cheap longer than you would like.
Your position could be dead money for a quarter or two.
Earnings risk cuts both ways. If Cooper misses on either segment, or guides fiscal Q4 below the Street, you will see another leg down.
The bar is not high, but medical device disappointments get punished hard right now, and a miss could take the stock back toward its 52-week low.
The company also has FX exposure through its international lens business. Dollar strength has been eating into reported results, with no sign of that easing. That is a headwind you cannot hedge away.
And honestly, the medical device sector remains out of favor. Sector rotation into these defensive corners has not happened yet. You are betting on being early, and being early can look wrong for weeks before it looks smart.
Quick Checklist
✅ Thesis still valid after the latest close
✅ Volume confirms accumulation on weakness
✅ Catalyst date double-checked (fiscal Q3 earnings, September 9, 2026)
Deep‑Dive Links
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!
Best Regards,
—Noah Zelvis
Everyday Alpha